Clinical management of Parkinson's disease dementia: Pitfalls and progress

Advances in Psychiatric Treatment

Volumn 12, Issue 2, 2006, Pages 121-129

  Samuel, Michael ^a   Maidment, Ian ^c   Boustani, Malaz ^c   Fox, Chris ^b  

^a UNIVERSITY OF KENT   (United Kingdom)

^b KENT AND MEDWAY NHS AND SOCIAL CARE PARTNERSHIP TRUST   (United Kingdom)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIPARKINSON AGENT; ARIPIPRAZOLE; CABERGOLINE; CHOLINESTERASE INHIBITOR; CLOZAPINE; DONEPEZIL; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; NEUROLEPTIC AGENT; OLANZAPINE; PLACEBO; PRAMIPEXOLE; QUETIAPINE; RISPERIDONE; RIVASTIGMINE; ROPINIROLE;

AGRANULOCYTOSIS; ARTICLE; BEHAVIOR DISORDER; CLINICAL FEATURE; CLINICAL TRIAL; COGNITIVE DEFECT; COMORBIDITY; CONSTIPATION; DEMENTIA; DEPRESSION; DIAGNOSTIC ACCURACY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DIAGNOSTIC PROCEDURE; DIPLOPIA; DIZZINESS; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG WITHDRAWAL; GASTROINTESTINAL SYMPTOM; HALLUCINATION; HEART DISEASE; HUMAN; HYPERSALIVATION; KIDNEY DYSFUNCTION; LEWY BODY; MEDICAL RESEARCH; MENTAL DISEASE; MOTOR DYSFUNCTION; NAUSEA; PARKINSON DISEASE; PATIENT CARE; RHINORRHEA; THROMBOSIS; TREMOR; VOMITING;

EID: 33644782515     PISSN: 13555146     EISSN: None     Source Type: Journal    
DOI: 10.1192/apt.12.2.121     Document Type: Article

References (56)

1. Aarsland, D., Larsen, J. P., Tandberg, E., et al (2000) Predictors of nursing home placement in Parkinson's disease: a population-based, prospective study. Journal of the American Geriatric Society, 48, 938-942.
2. Aarsland, D., Anderson, K., Larsen, J. P., et al (2001a) Risk of dementia in Parkinson's disease - a community-based, prospective study. Neurology, 56, 730-736.
3. Aarsland, D., Ballard, C., Larsen, J. P., et al (2001b) A comparative study of psychiatric symptoms in dementia with Lewy bodies and Parkinson's disease with and without dementia. International Journal of Geriatric Psychiatry, 16, 528-536.
4. Aarsland, D., Laake, K., Larsen, J. P., et al (2002) Donepezil for cognitive impairment in Parkinson's disease: a randomised control trial. Journal of Neurology, Neurosurgery and Psychiatry, 72, 708-712.
5. Aarsland, D., Ballard, C. G. & Halliday, G. (2004) Are Parkinson's disease with dementia and dementia with Lewy bodies the same entity? Journal of Geriatric Psychiatry and Neurology, 17, 137-145.
6. American Psychiatric Association (1994) Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) (4th edn). Washington, DC: APA.
7. Ballard, C., Margello-Lana, M., Juszczak, E., et al (2005) Quetiapine and rivastigmine and cognitive decline in Alzheimer's disease: randomized double blind placebo controlled trial. BMJ, 330, 857-858.
8. Barnes, J. & David, A. S. (2001) Visual hallucinations in Parkinson's disease: a review and phenomenological survey. Journal of Neurology, Neurosurgery and Psychiatry, 70, 727-733.
9. Barnes, J., Boubert, L., Harris, J., et al (2003) Reality monitoring and visual hallucinations in Parkinson's disease. Neuropsychologia, 41, 565-574.
10. Bohnen, N. I., Kaufer, D. I., Hendrickson, R., et al (2005) Cognitive correlates of cortical cholinergic denervation in Parkinson's disease and parkinsonian dementia. Journal of Neurology, 252, 9, doi: 10.1007/s00415-005-0971-0
11. Bracco, F., Battaglia, A., Chouza, C., et al (2004) The long-acting dopamine receptor agonist cabergoline in early Parkinson's disease: final results of a 5-year, double-blind, levodopa-controlled study. CNS Drugs, 18, 733-746.
12. Breier, A., Sutton, V. K., Feldman, P. D., et al (2002) Olanzapine in the treatment of dopamimetic-induced psychosis in patients with Parkinson's disease. Biological Psychiatry, 52, 438-445.
13. Brown, R. G., Scott, L. C., Bench, C. J., et al (1994) Cognitive function in depression: its relationship to the presence and severity of intellectual decline. Psychological Medicine, 24, 829-847.
14. Burn, D. J. & McKeith, I. G. (2003) Current treatment of dementia with Lewy bodies and dementia associated with Parkinson's disease. Movement Disorders, 18, S72-S79.
15. Burton, E. J., McKeith, I. G., Burn, D. J., et al (2004) Cerebral atrophy in Parkinson's disease with and without dementia: a comparison with Alzheimer's disease, dementia with Lewy bodies and controls. Brain, 127, 791-800.
16. Colloby, S. & O'Brien, J. (2004) Functional imaging in Parkinson's disease and dementia with Lewy bodies. Journal of Geriatric Psychiatry and Neurology, 17, 158-163.
17. Cummings, J. L. (1992) Depression and Parkinson's disease. American Journal of Psychiatry, 149, 443-454.
18. Dubois, B. & Pillon, B. (1997) Cognitive deficits in Parkinson's disease. Journal of Neurology, 244, 2-8.
19. Ellis, T., Cudkowicz, M. E., Sexton, P. M., et al (2000) Clozapine and risperidone treatment of psychosis in Parkinson's disease. Journal of Neuropsychiatry and Clinical Neurosciences, 12, 364-369.
20. Emre, M., Aarsland, D., Albanese, A., et al (2004) Rivastigmine for dementia associated with Parkinson's disease. New England Journal of Medicine, 351, 2509-2518.
21. Fabbrini, G., Barbanti, P., Aurilia, C. P., et al (2002) Donepezil in the treatment of hallucinations and delusions in Parkinson's disease. Neurological Sciences, 23, 41-43.
22. Factor, S. A., Molho, E. S. & Friedman, J. H. (2002) Risperidone and Parkinson's disease. Movement Disorders, 17, 221-222.
23. Fenélon, G., Mahieux, F., Huon, R., et al (2000) Hallucinations in Parkinson's disease: prevalence, phenomenology and risk factors. Brain, 123, 733-745.
24. Fernandez, H. H., Trieschmann, M. E. & Friedman, J. H. (2004) Aripiprazole for drug-induced psychosis in Parkinson's disease: preliminary experience. Clinical Neuropharmacology, 27, 4-5.
25. Firbank, M. J., Colloby, S. J., Burn, D. J., et al (2003) Regional cerebral blood flow in Parkinson's disease with and without dementia. Neuroimage, 20, 1309-1319.
26. Fox, C. G., Samuel, M., Beats, B., et al (2005) Memantine in Parkinson's disease dementia: clinical experience. Movement Disorders, 20, 418.
27. French Clozapine Parkinson Study Group (1999) Clozapine in drug-induced psychosis in Parkinson's disease. Lancet, 353, 2041-2042.
28. Friedman, J. H. & Factor, S. A. (2000) Atypical antipsychotics in the treatment of drug-induced psychosis in Parkinson's disease. Movement Disorders, 15, 201-211.
29. Gibb, W. R. & Lees, A. J. (1988) The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. Journal of Neurology, Neurosurgery and Psychiatry, 51, 745-752.
30. Goetz, C. G., Pappert, E. J., Blasucci, L. M., et al (1998a) Intravenous levodopa in hallucinating Parkinson's disease patients: high-dose challenge does not precipitate hallucinations. Neurology, 50, 515-517.
31. Goetz, C. G., Vogel, C., Tanner, C. M., et al (1998b) Early dopaminergic drug induced hallucinations in Parkinson's disease. Neurology, 51, 811-814.
32. Goetz, C. G., Blasucci, L. M., Leurgans, S., et al (2000) Olanzapine and clozapine: comparative effects on motor function in hallucinating PD patients. Neurology, 55, 789-794.
33. Graham, J. M., Sussman, J. D., Ford, K. S., et al (1998) Olanzapine in the treatment of hallucinosis in idiopathic parkinson's disease: a cautionary note. Journal of Neurology, Neurosurgery and Psychiatry, 65, 774-777.
34. Inzelberg, R., Kipervasser, S. & Korczyn, A. D. (1998) Auditory hallucinations in Parkinson's disease. Journal of Neurology, Neurosurgery and Psychiatry, 64, 533-535.
35. Juncos, J. L., Roberts, V. J., Evatt, M. L., et al (2004) Quetiapine improves psychotic symptoms and cognition in Parkinson's disease. Movement Disorders, 19, 29-35.
36. Klatka, L. A., Louis, E. D. & Schiffer, R. B. (1996) Psychiatric features in diffuse Lewy body disease: a clinicopathologic study using Alzheimer's disease and Parkinson's disease comparison groups. Neurology, 47, 1148-1152.
37. Kurita, A., Ochiai, Y., Kono, Y., et al (2003) The beneficial effect of donepezil on visual hallucinations in three patients with Parkinson's disease. Journal of Geriatric Psychiatry and Neurology, 16, 184-188.
38. Layton, D., Harris, S., Wilton, L. V., et al (2005) Comparison of incidence rates of cerebrovascular accidents and transient ischaemic attacks in observational cohort studies of patients prescribed risperidone, quetiapine or olanzapine in general practice in England including patients with dementia. Journal of Psychopharmacology, 19, 473-482.
39. Leroi, I., Brandt, J., Reich, S. G., et al (2004) Randomized placebo-controlled trial of donepezil in cognitive impairment in Parkinson's disease. International Journal of Geriatric Psychiatry, 19, 1-8.
40. Maidment, I. D., Fox, C. & Boustani, M. (2006) Cholinesterase inhibitors for Parkinson's disease dementia. Cochrane Database of Systematic Reviews, issue 1. Chichester: Wiley InterScience. DOI: 10.1002/14651858.CD004747.pub2.
41. McKeith, I. G., Galasko, D., Kosaka, K., et al (1996) Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology, 47, 1113-1124.
42. McKeith, I., Del Ser, T., Spano, P., et al (2000) Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study. Lancet, 356, 2031-2036.
43. Miwa, H., Morita, S., Nakanishi, I., et al (2004) Stereotyped behaviors or punding after quetiapine administration in Parkinson's disease. Parkinsonism and Related Disorders, 10, 177-180.
44. Morgante, L., Epifanio, A., Spina, E., et al (2004) Quetiapine and clozapine in parkinsonian patients with dopaminergic psychosis. Clinical Neuropharmacology, 27, 153-156.
45. Nilsson, F. M. (2004) Psychiatric and cognitive disorders in Parkinson's disease. Current Opinion in Psychiatry, 17, 197-202.
46. Ondo, W. G., Levy, J. K., Vuong, K. D., et al (2002) Olanzapine treatment for dopaminergic-induced hallucinations. Movement Disorders, 17, 1031-1035.
47. Parkinson Study Group (1999) Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson's disease. New England Journal of Medicine, 340, 757-763.
48. Parkinson Study Group (2000) Pramipexole v. levodopa as initial treatment for Parkinson disease: a randomized controlled trial. JAMA, 284, 1931-1938.
49. Pluck, G. C. & Brown, R. G. (2002) Apathy in Parkinson's disease. Journal of Neurology, Neurosurgery and Psychiatry, 73, 636-642.
50. Poewe, W. (2003) Psychosis in Parkinson's disease. Movement Disorders, 18 (suppl. 6), S80-S87.
51. Prueter, C., Habermeyer, B., Norra, C., et al (2003) Akathisia as side-effect of antipsychotic treatment with quetiapine in patient with Parkinson's disease. Movement Disorders, 18, 712-713.
52. Rascol, O., Brooks, D. J., Korczyn, A. D., et al (2000) A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. 056 Study Group. New England Journal of Medicine, 342, 1484-91
53. Rascol, O., Goetz, C., Koller, W., et al (2002) Treatment interventions for Parkinson's disease: an evidence based assessment. Lancet, 359, 1589-1598.
54. Samuel, M. & Colchester, A. C. F. (2005) Structural and functional magnetic resonance imaging in neurodegenerative diseases. In Neurodegenerative Diseases (eds M. F. Beal, A. E. Lang & A. E. Ludolph), pp. 253-289. Cambridge: Cambridge University Press.
55. Tandberg, E., Larsen, J. P., Aarsland, D., et al (1996) The occurrence of depression in Parkinson's disease: a community based study. Archives of Neurology, 53, 175-179.
56. Walker, Z., Costa, D. C., Walker, R. W., et al (2004) Striatal dopamine transporter in dementia with Lewy bodies and Parkinson's disease: a comparison. Neurology, 62, 1568-1572.